Newsroom der German Breast Group
In unserem Newsroom finden Sie Aktuelles rund um die German Breast Group.
15.02.2022 Save the date: AGO Mamma - State of the Art
Das AGO Mammakarzinom - State of the Art Meeting findet am 19. März 2022 online statt.
31.01.2022 January 2022: pCR in the breast and axillary lymph nodes correlates with iDFS – results from GeparOcto trial
We are pleased to inform you that an exploratory analysis of the randomized phase III GrparOcto trial has been published in Cancer
27.01.2022 GeparOcto: pCR in lymph nodes correlates with DFS
Exploratory analysis of GeparOcto patients published in "Cancers"
23.01.2022 Ankündigung: Mamma Mia! Patientenkongress
Deutschlands größter digitaler Patientenkongress zu Brust- und Eierstockkrebs am 5. und 6. Februar 2022
31.12.2021 December 2021: mdm2 gene amplification in luminal breast cancer
A biomarker analysis in luminal breast cancer using a humanized tumor mouse (HTM) model has been published in International Journal of Cancer.
31.12.2021 December 2021: CDK4/6 inhibitors in the treatment of patients with early breast cancer
We are delighted to inform you that an overview of data on CDK4/6 inhibitors in the treatment of breast cancer has been published in Breast.
17.12.2021 Erfahrungsbericht Brustkrebs in der Schwangerschaft
Erfahrungsbericht einer Betroffenen zur Diagnose und Behandlung eines Mammakarzinoms in der Frühschwangerschaft.
03.12.2021 GBG Research at SABCS 2021
We are happy to present our work at the San Antonio Breast Cancer Symposium, December 7-10 2021
30.11.2021 November 2021: Survival analysis of the randomised phase III GeparOcto trial
The survival analysis of the randomized phase III GeparOcto trial has been published in European Journal of Cancer
31.10.2021 October 2021: Association of RAD51 with HRD and clinical outcomes in untreated TNBC
An analysis evaluating RAD51 test and its association with HRD and clinical outcome in primary TNBC from GeparSixto trial has been published in Annals of Oncology.
19.10.2021 Fortbildungsempfehlung Molekulare Onkologie
Molekulare Onkologie in der Praxis – virtuelle Weiterbildungsveranstaltung am 27. Oktober, 17:00 bis 20:00 Uhr
30.09.2021 September 2021: iDFS and safety results of the randomized phase III GAIN-2 trial
We are delighted to inform you that our results on the GAIN-2 trial has been published in European Journal of Cancer
06.09.2021 GBG research at ESMO 2021
We are happy to present our work at ESMO 2021, September 16-21th
30.08.2021 August 2021: Utility of the CPS + EG scoring system in TNBC patients treated with neoadjuvant chemotherapy
We are delighted to inform you that our analysis on the utility of the CPS + EG score in triple-negative breast cancer patients has been published in European Journal of Cancer
19.07.2021 July 2021: Clinical and molecular characteristics of HER2-low-positive breast cancer
We are pleased to inform you that a pooled analysis of patients with HER2-low-positive breast cancer has been published in The Lancet Oncology
30.06.2021 June 2021: Chemotherapy-induced ovarian failure in young women with early breast cancer
A prospective analysis on chemotherapy-induced ovarian failure in young women with early breast cancer has been published in European Journal of Cancer
15.06.2021 Update-Seminar Klinische Pharmazie im September
Veranstaltungsempfehlung: 12. Klinische Pharmazie-Update-Seminar, 10. und 11. September 2021, Wiesbaden
01.06.2021 May 2021: Therapy response and prognosis of patients with low HR-positive, HER2-negative early breast cancer
A pooled analysis on therapy response and prognosis of patients with low HR-positive, HER2-negative early breast cancer has been published in European Journal of Cancer
